Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors.

Oncotarget - 25 Apr 2017

Kitazawa Satoshi, Ebara Shunsuke, Ando Ayumi, Baba Yuji, Satomi Yoshinori, Soga Tomoyoshi, Hara Takahito

Abstract excerpt

Mutations in succinate dehydrogenase B (SDHB) gene are frequently observed in several tumors and associated with poor prognosis in these tumors. Therefore, drugs effective for SDHB-deficient tumors could fulfill an unmet medical need. In addition, such drugs would have an advantage in that selection of patients with SDHB-mutant cancer could increase the probability of success in clinical trials. Currently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azepines
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Citric Acid Cycle

Share to Dehydroepiandrosterone

Share to Fumarates

Share to Heterocyclic Compounds, 4 or More Rings

Share to L-Lactate Dehydrogenase

Share to Succinic Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 28423651
DOI: 10.18632/oncotarget.15959
PMCID: PMC5438703

Genes

SDHB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors.PMID 28423651Read ↗

Knowledge-Based Therapeutics for Tricarboxylic Acid (TCA) Cycle-Deficient Cancers.Semantic proximity Read ↗

A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− ratsSemantic proximity Read ↗

The functional roles of TCA cycle metabolites in cancer.Semantic proximity Read ↗

Metabolic Effects of Succinate Dehydrogenase Loss in CancerSemantic proximity Read ↗

Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS.Semantic proximity Read ↗

Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors.Semantic proximity Read ↗

Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.Semantic proximity Read ↗

Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cellsSemantic proximity Read ↗

Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors.Semantic proximity Read ↗

Succinic Semialdehyde Dehydrogenase Deficiency: An Update.Semantic proximity Read ↗

Complex II subunit SDHD is critical for cell growth and metabolism, which can be partially restored with a synthetic ubiquinone analog.Semantic proximity Read ↗

Succinic Semialdehyde Dehydrogenase Deficiency: An UpdateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.